Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin + Metformin vs Synjardy in Healthy Volunteers
NCT06766500Phase 1Completed
- Sponsor
- Gedeon Richter Plc
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gedeon Richter Plc. Primary endpoints: Area under the concentration-time curve from time 0 to the last measurable concentration at 7 weeks and Maximum concentration in plasma at 7 weeks. Started Jan 2025; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06766500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766500.